Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Jee Hye Kang, Jeffrey A. Bluestone, Arabella Young
Trends in Immunology (2021) Vol. 42, Iss. 4, pp. 293-311
Closed Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
John B.A.G. Haanen, Michel Obéid, Lavinia Spain, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1217-1238
Open Access | Times Cited: 619
Immune-related adverse events of immune checkpoint inhibitors: a review
Qinan Yin, Liuyun Wu, Lizhu Han, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 139
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Kenji Chamoto, Tomonori Yaguchi, Masaki Tajima, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 10, pp. 682-695
Closed Access | Times Cited: 92
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Íñigo Les, Mireia Martínez, Inés Pérez-Francisco, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1629-1629
Open Access | Times Cited: 45
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
Ben Fleming, Paul Edison, Laura Kenny
BMJ (2023), pp. e071726-e071726
Closed Access | Times Cited: 42
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Muni Hu, Xiaolin Lin, Tiantian Sun, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 25
Leveraging NKG2D Ligands in Immuno-Oncology
Mercedes B. Fuertes, Carolina I. Domaica, Norberto W. Zwirner
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 94
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy
Laura A. Huppert, Michael D. Green, Luke Kim, et al.
Cellular and Molecular Immunology (2021) Vol. 19, Iss. 1, pp. 33-45
Open Access | Times Cited: 87
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Remo Poto, Teresa Troiani, Gjada Criscuolo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 67
Hematologic complications of immune checkpoint inhibitors
Michael H. Kroll, Cristhiam M. Rojas‐Hernandez, Cassian Yee
Blood (2021) Vol. 139, Iss. 25, pp. 3594-3604
Open Access | Times Cited: 58
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Fan Yang, Chloe Shay, Marin Abousaud, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 37
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
John E. Taylor, Aesha Gandhi, Elin S. Gray, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 26
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
Xiaoyu Gang, Jinshan Yan, Xin Li, et al.
Cancer Letters (2024) Vol. 604, pp. 217241-217241
Open Access | Times Cited: 12
PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells
Sarah C. Edwards, Ann Hedley, Wilma H. M. Hoevenaar, et al.
The Journal of Experimental Medicine (2022) Vol. 220, Iss. 2
Open Access | Times Cited: 37
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
Derek VanDyke, Marcos Iglesias, Jakub Tomala, et al.
Cell Reports (2022) Vol. 41, Iss. 3, pp. 111478-111478
Open Access | Times Cited: 32
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
Melissa G. Lechner, Mandy I. Cheng, Anushi Y. Patel, et al.
The Journal of Immunology (2022) Vol. 209, Iss. 4, pp. 696-709
Open Access | Times Cited: 30
MARCO is a potential prognostic and immunotherapy biomarker
Qingyu Dong, Shunhao Zhang, Haotian Zhang, et al.
International Immunopharmacology (2023) Vol. 116, pp. 109783-109783
Closed Access | Times Cited: 22
Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
Yixuan Yu, Shuo Wang, Zhening Liu, et al.
Chinese Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 18
Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias
Ying Yu, Ning Chen, Sizhe Yu, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 3, pp. 751-764
Open Access | Times Cited: 7
Current status and future of cancer vaccines: A bibliographic study
Rui Yu, Fangmin Zhao, Zeting Xu, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24404-e24404
Open Access | Times Cited: 7
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Ke Zhang, Xiangyi Kong, Yuan Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 25
Fecal Microbiota Transplantation Effectively Cures a Patient With Severe Bleeding Immune Checkpoint Inhibitor-Associated Colitis and a Short Review
Min-Min Chen, Mengyuan Liu, Chenyan Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 23
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
Priyatharcini Kejamurthy, K. T. Ramya Devi
Medical Oncology (2023) Vol. 41, Iss. 1
Closed Access | Times Cited: 13
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 5
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Jolanta Pach, Kailyn Valido, Annika Belzer, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 595-607
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top